Leap Historical Cash Flow

LPTX Stock  USD 2.95  0.03  1.03%   
Analysis of Leap Therapeutics cash flow over time is an excellent tool to project Leap Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 68.8 M or Depreciation of 14.2 K as it is a great indicator of Leap Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Leap Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Leap Therapeutics is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

About Leap Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Leap balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Leap's non-liquid assets can be easily converted into cash.

Leap Therapeutics Cash Flow Chart

At this time, Leap Therapeutics' Cash And Cash Equivalents Changes is fairly stable compared to the past year.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Leap Therapeutics financial statement analysis. It represents the amount of money remaining after all of Leap Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.
Most accounts from Leap Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Leap Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.At this time, Leap Therapeutics' Cash And Cash Equivalents Changes is fairly stable compared to the past year.

Leap Therapeutics cash flow statement Correlations

-0.060.130.09-0.37-0.110.0-0.260.080.430.130.090.04-0.010.28-0.080.18-0.010.23-0.130.81
-0.06-0.720.530.56-0.670.31-0.61-0.670.51-0.250.530.410.020.06-0.510.240.380.29-0.5-0.02
0.13-0.72-0.28-0.810.83-0.530.70.9-0.630.35-0.760.020.03-0.320.130.37-0.53-0.610.81-0.01
0.090.53-0.280.23-0.240.61-0.14-0.540.17-0.140.350.640.270.09-0.440.190.610.19-0.24-0.22
-0.370.56-0.810.23-0.420.47-0.58-0.760.63-0.560.450.00.280.32-0.32-0.420.460.66-0.84-0.16
-0.11-0.670.83-0.24-0.42-0.270.630.67-0.460.15-0.70.070.24-0.24-0.030.16-0.32-0.290.53-0.19
0.00.31-0.530.610.47-0.27-0.4-0.840.28-0.240.680.360.430.11-0.12-0.370.920.68-0.54-0.3
-0.26-0.610.7-0.14-0.580.63-0.40.65-0.720.58-0.76-0.2-0.26-0.270.350.06-0.43-0.630.73-0.23
0.08-0.670.9-0.54-0.760.67-0.840.65-0.560.35-0.82-0.23-0.21-0.260.20.37-0.81-0.710.780.15
0.430.51-0.630.170.63-0.460.28-0.72-0.56-0.40.38-0.060.190.55-0.37-0.230.330.74-0.860.57
0.13-0.250.35-0.14-0.560.15-0.240.580.35-0.4-0.37-0.27-0.26-0.040.510.02-0.32-0.20.440.01
0.090.53-0.760.350.45-0.70.68-0.76-0.820.38-0.370.280.010.22-0.07-0.180.70.49-0.56-0.11
0.040.410.020.640.00.070.36-0.2-0.23-0.06-0.270.280.18-0.48-0.760.70.41-0.030.02-0.28
-0.010.020.030.270.280.240.43-0.26-0.210.19-0.260.010.180.08-0.22-0.180.340.49-0.2-0.23
0.280.06-0.320.090.32-0.240.11-0.27-0.260.55-0.040.22-0.480.080.32-0.560.110.42-0.470.28
-0.08-0.510.13-0.44-0.32-0.03-0.120.350.2-0.370.51-0.07-0.76-0.220.32-0.62-0.16-0.140.27-0.11
0.180.240.370.19-0.420.16-0.370.060.37-0.230.02-0.180.7-0.18-0.56-0.62-0.3-0.50.430.07
-0.010.38-0.530.610.46-0.320.92-0.43-0.810.33-0.320.70.410.340.11-0.16-0.30.59-0.55-0.31
0.230.29-0.610.190.66-0.290.68-0.63-0.710.74-0.20.49-0.030.490.42-0.14-0.50.59-0.860.16
-0.13-0.50.81-0.24-0.840.53-0.540.730.78-0.860.44-0.560.02-0.2-0.470.270.43-0.55-0.86-0.22
0.81-0.02-0.01-0.22-0.16-0.19-0.3-0.230.150.570.01-0.11-0.28-0.230.28-0.110.07-0.310.16-0.22
Click cells to compare fundamentals

Leap Therapeutics Account Relationship Matchups

Leap Therapeutics cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash(12.4M)48.2M62.8M(49.4M)5.1M7.4M
Stock Based Compensation3.9M2.6M3.5M5.2M5.1M3.3M
Free Cash Flow(27.0M)(26.0M)(35.2M)(49.0M)(43.8M)(41.6M)
Change In Working Capital1.3M(990K)1.0M(651K)2.5M2.6M
Begin Period Cash Flow16.3M3.9M52.1M114.9M65.5M68.8M
Other Cashflows From Financing Activities(437K)25.8M813K(210K)(29K)(27.6K)
Depreciation47K34K29K16K15K14.3K
Other Non Cash Items732K634K527K855K30.0M31.5M
Total Cash From Operating Activities(26.9M)(26.0M)(35.2M)(49.0M)(43.8M)(41.6M)
Net Income(32.9M)(27.5M)(40.6M)(54.6M)(81.4M)(77.3M)
Total Cash From Financing Activities14.8M74.0M98.0M(210K)(30K)(28.5K)
End Period Cash Flow3.9M52.1M114.9M65.5M70.6M38.1M
Sale Purchase Of Stock1M25.5M813K0.0(1K)(950.0)
Investments(64K)0.0(85K)25K49.0M51.4M
Change To Account Receivables643K117K(1.2M)(1.0M)1.3M1.4M
Change To Netincome3.7M1.8M4.1M6.2M7.1M7.5M
Change To Liabilities368K(695K)(1.1M)3.9M1.1M1.3M
Change To Operating Activities250K147K(1.4M)(1.7M)(1.6M)(1.5M)
Cash And Cash Equivalents Changes(10.1M)(12.2M)48.1M62.9M72.3M75.9M
Cash Flows Other Operating483K2.9M(275K)(2.6M)(2.3M)(2.2M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.